Sanne de Jongh & Stefan Luzi
Sanne de Jongh joined Gilde Healthcare in 2017 and focuses on the biopharmaceutical sector. She is involved in deal sourcing, assessment of investment cases and portfolio management.
Prior to joining Gilde, Sanne was with Anterra Capital for three years, a global food and ag tech fund backed by Fidelity and Rabobank. Here she worked on several biotech investments, such as Caribou, Enko Chem and Agrimetis (board observer).
She began her career at MS Ventures, the biopharma fund of Merck KGaA, where she reviewed early stage strategic investments and supported the portfolio companies.
Sanne earned a masters degree (cum laude) in Biochemistry from Delft University of Technology, with a specialization in Neurology at the LUMC, the Netherlands. She is part of the Global Shapers Community of the World Economic Forum.
Stefan Luzi, Partner, Gilde Healthcare
Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on venture and growth capital investments in the biopharmaceutical and life science instruments sectors. He led the investment in Lava Therapeutics B.V. and was part of several other investments. He represents Gilde on the boards of Lava Therapeutics B.V. and Lumicks B.V.
Prior to joining Gilde, Stefan worked at Merck KGaA where he completed several international assignments including the Global Business Intelligence and MS Ventures divisions. Additionally, he was involved in various consulting projects spanning the pharmaceutical and chemical departments at Merck and co-moderated Merck Serono's innovation competitions.
Stefan holds a MSc in Biotechnology degree from ETH Zurich (Switzerland) and a MPhil in Bioscience Enterprise degree from the University of Cambridge (UK). He also completed a PhD program with Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge (UK), where he developed a bicyclic peptide-based drug discovery platform.
Gilde Healthcare (Utrecht, The Netherlands and Cambridge, USA) is a transatlantic venture and growth capital firm focused on private healthcare companies. It has over €800 million under management and is actively looking to lead new investments in digital health, medical devices, therapeutics and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €30 million in a single portfolio company.